Peritoneal absorption of moxalactam.

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Peritonitis is a common complication in patients with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD).
• Systemic absorption of antibiotics administered via the intraperitoneal route is crucial for effective treatment in these patients.
• Moxalactam is a third-generation cephalosporin with broad-spectrum activity.

Purpose of the Study:

• To evaluate the pharmacokinetic profile of moxalactam administered intraperitoneally in CAPD patients with peritonitis.
• To determine the rate and extent of systemic absorption of moxalactam in this specific patient population.

Main Methods:

• Moxalactam was administered intraperitoneally at an initial dose of 200 mg/2L dialysate, followed by 60 mg/2L for subsequent 1-hour exchanges.
• Serum moxalactam concentrations were measured at various time points, including after the first hourly dialysis and up to 24 hours.
• Minimal inhibitory concentrations (MICs) for relevant microorganisms were considered for comparison.

Main Results:

• Mean serum moxalactam concentration was 2.5 +/- 0.9 mg/L after the first hour and increased to 10.3 +/- 4.8 mg/L after 24 hours.
• Serum levels at 1 hour exceeded MICs for most gram-negative organisms, excluding Pseudomonas aeruginosa.
• No adverse effects related to moxalactam administration were reported during the study.

Conclusions:

• Intraperitoneal administration of moxalactam results in significant systemic absorption in CAPD patients with peritonitis.
• Achieved serum concentrations suggest potential efficacy against a range of gram-negative pathogens, though Pseudomonas aeruginosa may require alternative treatment.
• Moxalactam appears to be well-tolerated in this patient group.